View Older Stories View More Recent Stories

Feb 24, 2020 08:07AM Bristol-Myers Squibb (BMY), CytomX Therapeutics (CTMX) Begin Randomized Ph.2 Cohort Expansion in Ongoing Phase 1/2a Clinical Trial of Anti-CTLA-4 Probody Therapeutic BMS-986249
Feb 21, 2020 07:01AM Bristol-Myers Squibb (BMY) Reports Japanese Health Ministry Approval for Opdivo (nivolumab) for Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer
Feb 21, 2020 06:59AM Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer
Feb 19, 2020 06:59AM  Bristol-Myers Squibb to Hold Investor Day on April 2
Feb 15, 2020 02:30PM Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma
Feb 15, 2020 01:00PM Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Feb 14, 2020 06:30AM Multinational Inflammatory Bowel Disease Survey Uncovers Striking Differences in Patients’ and Physicians’ Treatment Goals and Disease Management Expectations
Feb 13, 2020 07:17AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review its BLA for Lisocabtagene Maraleucel for Adult Patients with R/R Large B-Cell Lymphoma
Feb 13, 2020 06:59AM U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapse
Feb 6, 2020 07:05AM Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
Feb 4, 2020 07:00AM BioMotiv and Bristol-Myers Squibb Announce the Launch of Anteros Pharmaceuticals
Jan 31, 2020 04:17PM Bristol-Myers Squibb (BMY) Withdraws European Application of Opdivo Plus Yervoy for First-Line Treatment of Advanced NSCLC
Jan 31, 2020 04:16PM Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Jan 30, 2020 07:22AM FORMA Therapeutics Achieves Early-Stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb (BMY)
Jan 30, 2020 07:05AM FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb
Jan 15, 2020 07:01AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review its Application for Opdivo Plus Yervoy in First-Line Non-Small Cell Lung Cancer
Jan 15, 2020 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
Jan 10, 2020 07:00AM Nektar Therapeutics (NKTR), Bristol-Myers Squibb (BMY) Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo
Jan 10, 2020 06:59AM Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
Jan 9, 2020 07:00AM Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce NEJM Publishes Results of Pivotal Phase 3 Reblozyl MEDALIST Trial
Jan 9, 2020 06:59AM New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Jan 7, 2020 03:00AM Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy  
Jan 7, 2020 01:40AM Evotec And Bristol-Myers Squibb Expand iPSC Collaboration
Jan 6, 2020 04:16PM Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 2, 2020 06:59AM Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
Dec 20, 2019 07:00AM Bristol-Myers Squibb (BMY) Receives EC Approval for Revlimid in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma
Dec 20, 2019 06:59AM Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma
Dec 19, 2019 06:59AM Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020
Dec 18, 2019 04:19PM Bristol-Myers Squibb (BMY) Reports Submission of Biologics License Application to FDA for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel)
Dec 18, 2019 04:16PM Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA
Dec 13, 2019 07:00AM Bristol-Myers Squibb Announces Leadership Changes
Dec 10, 2019 07:31AM Bristol-Myers Squibb (BMY) Presents OS and Safety Data From Pivotal CC-486 Study QUAZAR AML-001
Dec 10, 2019 07:30AM Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001
Dec 10, 2019 05:58AM bluebird bio (BLUE), Bristol-Meyers Squibb (BMY) Highlight Updated Data from Ongoing Ph. 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma
Dec 9, 2019 06:15PM bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and
Dec 9, 2019 04:47PM Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce Reblozyl Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at ASH
Dec 9, 2019 04:30PM Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Dec 8, 2019 04:30PM Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting
Dec 7, 2019 04:00PM Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
Dec 7, 2019 02:00PM Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
Dec 6, 2019 04:17PM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announce Positive Top-line Results from Pivotal Phase 2 KarMMa Study of Ide-cel in R/R Multiple Myeloma
Dec 6, 2019 04:16PM Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
Dec 6, 2019 12:07PM Bristol-Myers Squibb (BMY), Acceleron Pharma (XLRN) Announces FDA Will Not Review Reblozyl at ODAC Meeting
Dec 6, 2019 12:05PM Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
Dec 5, 2019 04:16PM Bristol-Myers Squibb Announces Dividend Increase
Dec 4, 2019 07:02AM Bristol-Myers Squibb (BMY) Announces FDA Breakthrough Therapy Designation for ORENCIA to Help Prevent Acute Graft-Versus-Host Disease
Dec 4, 2019 06:59AM Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After St
Dec 3, 2019 07:39AM Bristol-Myers Squibb (BMY), Acceleron Pharma (XLRN) Announce FDA Advisory Committee Will Review Reblozyl for Use in Patients With Myelodysplastic Syndromes
Dec 3, 2019 07:38AM Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes
Nov 26, 2019 06:59AM Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights
View More Recent Stories View Older Stories